Clinical Trials
68 trialsNCT05949632 2026-06-04
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
Incyte Corporation
Phase 1/2 Terminated
NCT03595124 2026-05-29
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02535533 2026-05-06
SLM + Axitinib for Clear Cell RCC
University of Iowa
Phase 1/2 Completed
NCT01744249 2026-04-28
Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
Grupo Espanol de Tumores Neuroendocrinos
Phase 2/3 Completed
NCT04355156 2026-04-16
AXMUS-C
Imperial College London
Phase 2 Completed
NCT02853331 2026-02-02
KEYNOTE-426
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04585815 2026-01-09
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Pfizer
Phase 1/2 Terminated
NCT04370509 2025-11-19
Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery
University of California, San Francisco
Phase 2 Terminated
NCT02684006 2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3 Completed
NCT02912572 2025-07-10
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT00828919 2024-12-03
Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials
Pfizer
Phase NA Completed
NCT01693822 2024-11-21
A-PREDICT
Institute of Cancer Research, United Kingdom
Phase 2 Completed
NCT02639182 2024-11-18
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Astellas Pharma Inc
Phase 2 Completed
NCT03990571 2024-10-18
Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02667886 2024-10-03
Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma
X4 Pharmaceuticals
Phase 1/2 Completed
NCT01263769 2024-09-19
Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02636725 2024-07-12
Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas
University of Miami
Phase 2 Completed
NCT03472560 2024-04-09
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
Pfizer
Phase 2 Terminated
NCT03386929 2023-12-18
SPRING
Worldwide Innovative Network Association
Phase 1/2 Terminated
NCT02579811 2023-06-29
Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT05249569 2023-05-03
Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT01385059 2023-03-07
Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer
City of Hope Medical Center
Phase 2 Completed
NCT00920816 2022-05-06
Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer
Pfizer
Phase 3 Completed
NCT02493751 2022-02-18
JAVELIN Renal 100
Pfizer
Phase 1 Completed
NCT02129647 2021-12-01
Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
NYU Langone Health
Phase 2 Completed
NCT01649180 2021-08-12
PrE0801
PrECOG, LLC.
Phase 2 Terminated
NCT02133742 2021-07-28
A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer
Pfizer
Phase 1 Completed
NCT03494816 2021-06-30
NAXIVA
Scottish Clinical Trials Research Unit
Phase 2 Completed
NCT02762513 2021-05-05
Expansion Trial for Axitinib In Head And Neck Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT01321437 2021-01-20
Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
University of California, Irvine
Phase 2 Completed
NCT01967576 2021-01-06
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01806064 2020-10-19
Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma
Tracon Pharmaceuticals Inc.
Phase 1/2 Terminated
NCT01999972 2020-09-24
A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT03289533 2020-09-04
A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)
Pfizer
Phase 1 Completed
NCT01490866 2019-09-24
A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01599754 2019-09-20
ATLAS
SFJ Pharmaceuticals, Inc.
Phase 3 Terminated
NCT00569946 2019-06-05
Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)
Pfizer
Phase 2 Completed
NCT00219557 2019-05-14
AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer
Pfizer
Phase 2 Completed
NCT00678392 2019-01-09
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
Pfizer
Phase 3 Completed
NCT01210495 2019-01-09
Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma
Pfizer
Phase 2 Completed
NCT01441414 2019-01-08
PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Pfizer
Phase 2 Terminated
NCT02560012 2018-10-12
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT01435122 2018-10-02
A Study of Axitinib in Advanced Carcinoid Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01174238 2018-06-08
A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma
University of California, San Francisco
Phase 2 Completed
NCT01533948 2018-05-09
Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery
Roswell Park Cancer Institute
Phase 2 Terminated
NCT01558661 2017-11-28
Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01508117 2017-09-19
Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients
University of Cincinnati
Phase 2 Terminated
NCT00835978 2017-05-30
Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer
Pfizer
Phase 2 Completed
NCT01469546 2016-08-29
Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT00768755 2015-10-28
Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer
Pfizer
Phase 1/2 Completed